Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FJQ24
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,064
Award facts
- Contract value 100% obligated
- $42,063.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $42,064 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price delivery order, issued on August 25, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat inflammatory conditions including atopic dermatitis, asthma, and chronic rhinosinusitis, and its procurement through the DLA reflects ongoing federal demand for specialty pharmaceuticals to support military and veteran healthcare systems.
This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. As a primary pharmaceutical vendor for the federal government, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The IDC vehicle enables the company to fulfill pharmaceutical requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems on a global basis, with the DLA planning to expand its pharmaceutical prime vendor program to include multiple regional contractors in future iterations.
Quick answers
Who was awarded contract SPE2DB25FJQ24?
SPE2DB25FJQ24 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FJQ24 worth?
The government has obligated $42,064 on SPE2DB25FJQ24.
Is contract SPE2DB25FJQ24 an order under another contract?
Yes. SPE2DB25FJQ24 is a delivery order under SPE2DB22D2206, an indefinite delivery contract.
Was contract SPE2DB25FJQ24 competed?
The extent of competition for SPE2DB25FJQ24 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award